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Abstract 
Studies on cognitive behavioural therapy for psychosis (CBTp) have developed from evaluating generic 
approaches to focusing on specific symptoms. The evidence for targeted studies on delusions and 
hallucinations was reviewed. We included randomized controlled trials (RCTs) examining the effect of 
individualized CBT-based interventions focusing either on delusions or on hallucinations. Twelve suitable 
RCTs were identified. Four RCTs focused on delusions, of which three took a focused approach targeting 
mechanisms assumed causal to persecutory delusions. Eight RCTs focused on hallucinations, a common 
component of these studies being a focus on the perceived power imbalance between the voice(s) and 
the voice-hearer, to reduce distress and dysfunction. Only three RCTS were powered adequately; the 
remainder were pilot trials. All trials reported effect sizes against treatment-as-usual above d = 0.4 on at 
least one primary outcome at post-therapy, with several effects in the large range. Effects on the 
primary outcome were maintained for five of the seven studies that had significant outcomes and 
reported a follow-up comparison, but most of the follow-up periods were brief. 
Although targeted studies are still in their infancy, the results are promising with a tendency 
towards higher effects compared to the small-to-moderate range found for generic CBTp. In clinical 
practice, CBTp will need to continue including a range of approaches that can be adapted to patients in a 
flexible manner according to the primary goals and prevalent combination of symptoms. However, 
symptom-focused and causal-interventionist approaches are informative research strategies to evaluate 
the efficacy of separate components or mechanisms of generic CBTp. 
Keywords: Cognitive Behaviour Therapy, Delusions, Hallucinations, Psychosis, Symptom-focused 
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Introduction 
Cognitive Behaviour Therapy for psychosis (CBTp) is an accepted, adjunct psychological therapy 
for individuals suffering from distressing psychotic symptoms. The main instrument of change in CBTp 
involves reframing appraisals and modifying behavior related to psychotic symptoms, to reduce distress 
and improve functioning and well-being. Therapy is collaborative, based on a shared formulation, and 
uses a normalizing philosophy (Morrison and Barratt, 2010). It is geared towards achieving the person’s 
personal valued goal(s), with paramount importance being given to the therapeutic relationship and 
empowerment, maintaining the person’s self-esteem, and providing hope (Brabban et al., 2017). Due to 
the heterogeneity of presentation in psychosis, a range of therapy approaches have been developed, 
reflected in the many books and manuals currently available (see Johns et al., 2014). 
Randomized controlled trials (RCTs) of CBTp have tended to comprise composite CBTp 
approaches for heterogeneous groups of patients, addressing different types of symptoms. To date, 
there have been >20 meta-analyses reviewing up to 50 RCTs. The effect sizes across these meta-analyses 
range from 0.09 (Velthorst et al., 2015) to 0.93 (Gould et al., 2001), depending on the permutations of 
trials included, for instance whether they focused on specific populations (e.g., treatment resistant 
patients, Burns et al., 2014), type of therapy (e.g., formulation-based therapies, van der Gaag et al., 
2014), outcomes (e.g., negative symptoms, Lutgens et al., 2017), assessment time-point (e.g., end of 
therapy, Jauhar et al., 2014), or comparison group (e.g., active control, Turner et al., 2014). For the 
primary outcome (generally an overall symptomatology measure) the average effect is in the small to 
moderate range (d=0.40; Wykes et al., 2008), with smaller effects in methodologically rigorous trials 
(Jauhar et al., 2014). 
However the value of combining highly heterogeneous trials with different foci has been 
questioned (Byrne, 2014; Peters, 2014), since such analyses reflect an over-simplification of the 
complexities of psychosis presentations and of the range of psychological interventions encompassed 
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within a broad CBTp framework (Thomas, 2015). Meta-analyses focusing on individually tailored, 
formulation-based approaches (van der Gaag et al., 2014), and reporting effect sizes for individual 
symptoms (Mehl et al., 2015; Naeem et al., 2016; van der Gaag et al., 2014), have been more 
informative about the specific effects of CBTp on delusions and hallucinations. These analyses are 
consistent in showing small-to-moderate effect sizes for hallucinations (0.44, van der Gaag et al., 2014; 
0.45, Naeem et al., 2016) and delusions (0.36, van der Gaag et al., 2014; 0.56 Naeem et al., 2016), 
although the results are less consistent for the smaller number of trials comparing CBTp with other 
psychological interventions (Turner et al., 2014). 
One limitation is that even in the meta-analyses reporting effect sizes on specific symptoms, the 
studies selected were not necessarily RCTs where the therapy focused on a particular symptom, but 
included mostly trials with heterogeneous patients and generic CBTp approaches, with secondary 
outcome measures of delusions and hallucinations. The findings may therefore underestimate effects, 
since the studies may not have been powered for the secondary outcomes. Moreover, it is possible that 
presenting symptoms may not have been targeted by the therapy, depending on the individual’s goals. 
One meta-analysis looking at outcomes on delusions (Mehl et al., 2015) compared generic CBTp 
approaches to newer studies taking a ‘causal-interventionist approach’ (Freeman, 2011). They found a 
difference of 0.33 in mean effect sizes in favor of the newer studies, where patients were selected for 
the presence of persecutory delusions, the therapy focused specifically on hypothesized maintenance 
factors, and the primary outcomes assessed the actual focus of therapy. 
In this paper, we review and discuss the empirical evidence for ‘targeted’ studies on delusions and 
hallucinations; i.e., trials that evaluate components of generic CBTp focusing on specific symptoms. In 
order to facilitate the interpretation of any differences in outcome, we sought to increase the 
comparability of studies in terms of the type of interventions used, and only included studies where the 
approach was entirely individualized to the patient rather than relying on a manualized training 
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approach or being group-based; the therapy focused on formulating and changing either hallucinations 
or delusions, or factors closely associated with the symptom, such as distress (e.g. hallucination related 
distress), behavior (e.g. acting on hallucinations), or maintenance process (e.g., worry); and the primary 
outcome(s) reflected the focus of therapy. Third wave and ‘new’ approaches were included if they 
exhibited similar goals to CBTp, i.e., disrupting the associations between the presence of psychotic 
symptoms and their emotional and behavioural sequelae, even if the ‘road-map’ to achieving these 
changes diverged from traditional CBTp. As the number of studies was small and studies differed in the 
type and intensity of the intervention employed, we opted for a discursive review rather than a 
quantitative effect-integration. This approach is more suitable when the main aim is to reflect on the 
differences between therapeutic approaches and their outcomes and to derive implications for future 
research. 
 
Method 
Suitable peer-reviewed articles in English were identified in March 2017 by conducting two 
separate literature searches (delusion- and hallucination-focused) in electronic databases (MEDLINE and 
PsycINFO) via Ovid. The following search terms were used: 
("CBT", "cognitive behavio*", or "cognitive-behavio*", or "intervention", or "therapy", or 
"training" or “treat*” or “trial”) were either combined with ("delusion", or "paranoia") or with 
("hallucination* or voice*"). 
Moreover, reference lists of previous meta-analyses and book chapters on psychological 
approaches to psychosis were screened for suitable studies. In a second and third step, titles followed 
by abstracts were screened for relevance. The remaining articles were examined in detail regarding the 
predefined inclusion and exclusion criteria. Inclusion criteria encompassed (a) English studies describing 
(b) RCTs examining the effect of (c) individualized CBT-based interventions focusing on (d) delusions or 
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hallucinations. Criterion (d) was considered fulfilled if 1) the description of the intervention clearly 
described the focus to be on either delusions or hallucinations rather than on psychopathology in 
general, and if 2) the trial EITHER used a measure of delusions or hallucinations as a primary outcome 
OR excluded participants below a predefined cut-off score for delusions and hallucinations. Exclusion 
criteria were (a) subclinical or at-risk samples, (b) group-therapy, (c) manualized training protocols.  
Controlled effect sizes are those reported in the original studies, and are based on the post- or 
follow-up differences between the intervention and the control group with or without controlling for 
pre-assessment scores. Where controlled effect sizes were not reported but mean values and standard 
deviations, or odd ratios, were provided, the Cohen’s d effect sizes were calculated (see Tables 1 & 2). 
Results 
The literature search revealed 507 peer-reviewed studies for delusions and 1,293 for 
hallucinations after removing duplicates. After the selection process (see Figure 1), four studies on 
delusions and six on hallucinations met the full inclusion criteria. A further two studies were trial 
protocols at the time of the literature search, but were published during the revision process and thus 
included, making a total of eight RCTs for hallucinations. Details on studies, including sample sizes, 
target population, therapy format, measurement time points, dropout-rates and effects sizes for 
primary and key secondary outcomes are provided in Tables 1 (delusions) and 2 (hallucinations). 
Of the 12 studies included eight used a treatment-as-usual (TAU) control group, one used a 
waitlist control, one used an attention control, one used a supportive counselling control, and one used 
both a waitlist and a placebo control (befriending) condition. Nine included a follow-up
1
 (range: 1 to 9 
months).  
                                                 
1
 One of the nine studies (Leff et al, 2013) included a follow-up assessment but did not present any 
comparisons between groups at that time-point. 
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The sample sizes across all studies varied from 24 to 197. The dropout rate from the CBT 
interventions varied from zero to 35% (mean: 20.5% hallucinations; 11% delusions). In the following 
sections we provide a brief summary of the design, the intervention and the main results of each of the 
selected studies. 
 
Studies focusing on Delusions 
O’Connor and colleagues (2007) compared an individualized CBT approach to an attention 
placebo group in a small sample of patients diagnosed with delusional disorder. The intervention 
followed early descriptions of CBTp (Chadwick and Lowe, 1994; Garety et al., 1994) and consisted of up 
to 24 sessions with a focus on cognitive reframing and reality testing. In support of the main hypothesis 
that ‘dimensions of delusional beliefs and associated distress’ (primary outcome) would improve, 
significant benefits of the CBT over the control condition were found for 1/3 of the items of the 
Maudsley Assessment of Delusions Scale (MADS; Wessely et al., 1993), including subjective strength of 
conviction, reactions to and acting on beliefs. The effect sizes of these items were in the small to 
medium range. However since there was a 50% attrition rate in the control group, and neither a specific 
primary outcome dimension on the MADS nor a criterion of success were predefined in this trial, it is 
difficult to interpret the overall success of the intervention. 
Freeman and colleagues (2015a) evaluated the effect of six sessions of individual worry-focused 
CBT compared to TAU on worry (primary outcome I and hypothesized mediator) and overall delusions 
(primary outcome II). This study was preceded by a small pilot trial (Foster et al., 2010) that focused on 
worry and paranoia distress as primary outcomes. The intervention included psychoeducation, 
reviewing of positive and negative beliefs about worry, increasing awareness of the initiation of worry 
and identification of worry-triggers, learning to let go of worry, implementation of worry periods, 
problem-solving and relaxation exercises. In both trials worry scores reduced in the intervention group 
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at post-treatment compared to TAU, and improvement was maintained, with medium-to-large and 
small effect sizes in the two-months follow-up in the pilot trial and the four-month follow-up in the main 
trial, respectively. Moreover, there were large and small-to-medium effect sizes for the Psychotic 
Symptoms Rating Scale (PSYRATS) delusions subscale (Haddock et al., 1999) in the pilot and main trial, 
respectively, although the pilot trial did not show the expected effect on its primary outcome, paranoia 
distress. The main trial also found small effects for several of the secondary outcome measures, 
including delusion distress. Worry mediated the intervention effect on delusions, accounting for 66% of 
the change. 
In an early phase II trial, Freeman and colleagues (2014) investigated the effect of a six-session 
CBT intervention focused on reducing negative thoughts and enhancing positive thoughts about the self, 
and increasing positive activities, compared to TAU. Negative thoughts were normalized, made 
understandable within the person’s life context, and reviewed. Patients were encouraged to increase 
valued activities, and positive thoughts were encouraged by reviewing strengths and keeping a diary of 
positive events. The therapy was supported between sessions by telephone calls, texts and supportive 
visits from a graduate student. There was a small non-significant effect for negative self-concepts 
(primary outcome I, hypothesized mediator) and a moderate non-significant effect for paranoia (primary 
outcome II). There were significant moderate to large effects in several of the secondary outcomes (e.g. 
positive self-concepts, self-esteem, social-rank), but none of the benefits was maintained four weeks 
later. 
 
Studies focusing on hallucinations 
The largest studies to date are the COMMAND (Birchwood et al., 2014) and Avatar Therapy 
(Craig et al., In Press) trials, both of which were preceded by pilot trials (Leff et al, 2013; Trower et al., 
2004). The remaining four studies are all pilot trials. 
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The focus of Cognitive Therapy for Command Hallucinations (CTCH, Birchwood et al., 2014) was 
to reduce harmful compliance behavior through reducing the power imbalance between the voice(s) 
and the voice-hearer. This was achieved by enhancing coping strategies to increase perceived 
controllability over the voices, modifying appraisals about the power of the voices to carry out their 
malevolent intent, reducing safety behaviours and ‘appeasement’ of the voices, and addressing 
subordinate interpersonal schema (see Meaden et al., 2013), for a fuller description). CTCH was 
delivered over 9 months for approximately 25 sessions. Both the pilot and main study found significant 
reductions in compliance behavior (primary outcome) in the therapy compared to the TAU group, with 
large and small-to-medium effect sizes, respectively, for up to 9 months post-therapy. As predicted, 
both studies also showed significant differences between the groups post-therapy on the Voice Power 
Differential scale (VPD; Birchwood et al., 2004), which was demonstrated to be the mediator of change 
in the main trial (Birchwood et al., 2017). However, contrary to expectations, there was either no 
significant impact on voice-related distress (Birchwood et al., 2014), or post-therapy reductions were 
not maintained at the six months follow-up (Trower et al., 2004). 
One other, smaller study also targeted command hallucinations (Treatment of Resistant 
Command Hallucinations; TORCH; Shawyer et al., 2012), using a CBTp protocol aimed at changing power 
beliefs, as well as beliefs about the self and associated delusions when applicable. Therapy was 
augmented with Acceptance and Commitment Therapy (ACT; Bach and Hayes, 2002) strategies, such as 
just noticing and accepting voices and associated thoughts, rather than believing or acting on them; 
accomplishing valued goals despite voices; and mindfulness exercises. TORCH was delivered for 
approximately 15 weekly sessions with two follow-up sessions, and compared to both waiting-list and 
befriending. In contrast to the COMMAND trial, no differences were found between the TORCH and 
befriending groups on command hallucination compliance, resistance or coping (primary outcomes) or 
on any of the secondary outcomes. The TORCH group showed increased confidence in coping with 
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command hallucinations compared to the waiting-list group, with a large effect size, but both TORCH 
and befriending produced pre-post therapy gains on that measure, which were not maintained at the six 
months follow-up. However, these results should be interpreted with caution, since 42% of the 
participants showed no compliance at baseline, which undermines both the focus of the therapy and the 
primary outcome measures used. 
The other five trials focused on distressing, persistent voices across diagnostic groups. Avatar 
therapy is an innovative therapy that uses computer technology to create an Avatar of each individual’s 
voice, which is then controlled by the therapist in interaction with the patient (see Leff et al., 2014 and 
Craig et al., 2016 for a fuller description). The Avatar enables a powerful but safe ‘exposure’ to the 
persecuting voice, leading to an increased sense of control and mastery over the voice as the Avatar 
changes from being abusive to supportive. In addition, Avatar therapy includes making links between 
low self-esteem and the content of critical voices, with a focus on the individual’s strengths and 
capabilities. Both the pilot and main trials reported that six weekly sessions (plus one assessment (main 
trial) or follow-up (pilot trial) session) produced a large and significant effect on the total score of the 
PSYRATS- auditory hallucinations (AH) subscale (Haddock et al., 1999) (primary outcome), compared to 
the control group (a delayed therapy group in the pilot, and supportive counselling in the main trial), at 
the end of therapy (12 weeks). The main trial also found significant effects on voice frequency and 
distress, on the omnipotence (but not the malevolent) scale of the Beliefs about Voices Questionnaire 
(BAVQ-R; Chadwick et al., 2000), and on the Voice Acceptance and Action Scale (Shawyer et al., 2007) 
(secondary outcomes), but not on affective or other psychotic symptoms. However none of the 24-
weeks follow-up group comparisons on either primary or secondary outcomes was significant. 
Making links between low self-esteem and the content of critical voices was the main focus of 
competitive memory training (COMET; van der Gaag et al., 2012). In the COMET trial, memories 
associated with positive self-esteem were retrieved and strengthened. The activation of this positive 
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self-image was then used to weaken the negative content of voices and enhance self-confidence. The 
aim was to change the submissive relationship to the voices, through reappraising their meaning and 
reducing their emotional impact. In contrast to Avatar Therapy, seven sessions of COMET did not affect 
the total PSYRATS-AH score post-therapy, although a medium effect size was reported for the cognitive 
interpretation of voices dimension compared to TAU (secondary outcome) (van der Gaag et al., 2012). 
Importantly, the authors found a medium-to-large effect on depressive symptoms, their primary 
outcome. This effect was fully mediated by self-esteem and acceptance of voices, and partially mediated 
by the attributed power to the voices and the social ranking of oneself in relation to the voices, which 
were all hypothesized mediators. 
Two small pilot trials examined Relating therapy (Hayward et al., 2014) and a guided self-help 
approach based on the ‘Overcoming Distressing Voices’ book (Hayward et al., 2012). The Relating 
Therapy RCT (Hayward et al., 2017) was delivered over 16 sessions, and aimed to change subordinate 
and negative styles of relating to the voice(s) through assertiveness training, in relation to both voices 
and other individuals in the person’s social environment, and drawing on the individual’s history of 
interpersonal attachment patterns. A guided self-help CBT for voices (CBTv; Hazell et al., In Press) 
consisted of eight sessions over a maximum of 12 weeks, with each session linked to a specific chapter 
in the self-help book and accompanying workbook. Therapy aimed to reduce voice impact through 
‘modules’ targeted at coping  with voices, reducing negative beliefs about self and voices, and increasing 
assertiveness in relationships. These two trials reported the highest effect sizes of all the reviewed 
studies on their primary outcomes at the end of therapy, namely voice-related distress and voice-impact, 
respectively. The large effect size on voice-related distress for Relating Therapy was maintained 20 
weeks later, with other improvements being evident at both time points on a number of secondary 
outcomes, including depression and well-being (effect sizes ranging from small to large). Similarly, the 
guided self-help CBTv also found a range of improvements on secondary and mechanism outcomes at 
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the end therapy (no follow-up was done). However for both studies a large number of secondary 
outcomes were looked at, which, coupled with the small sample size, mean that these positive results 
need to be interpreted with caution. 
 
Discussion 
This review synthesized research evaluating the effect of targeted, individualized cognitive 
behavioral interventions focusing specifically on delusions and hallucinations. This research strategy is in 
its infancy, with only 12 studies adopting this approach, of which nine were pilot trials. Nevertheless, the 
results are highly promising. All trials reported effect sizes against treatment-as-usual above d = .4 on at 
least one primary outcome at post-therapy and several effects in the large range, indicating a tendency 
towards higher effects compared to the small-to-moderate range found for generic CBTp trials (Wykes 
et al, 2008; Jauhar et al., 2014). The effects were generally maintained at follow-up, but follow-up 
periods were brief. Overall, the findings suggest that targeted individualized CBT for delusions and 
hallucinations is effective in reducing its target outcomes. 
 
Main findings 
With regards to the studies focusing on delusions, it is notable that, with the exception of an 
older study by O’Connor and colleagues (2007), the studies were all conducted in one research group. 
All took the approach of targeting ‘causal’ psychological factors, and all targeted persecutory delusions 
exclusively. The pilot and main trial targeting worry were both successful in reducing persecutory 
delusions (Foster et al., 2010; Freeman et al., 2015a), making this a robust finding, but longer follow-up 
periods would be informative to test for stability of effects. The intervention focusing on self-concepts 
found no effects on negative self-cognitions and a moderate but non-significant effect on paranoia. 
Moreover, secondary benefits on positive self-concepts were short-lived. A similar pattern of findings 
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was found in an experimental study testing the effect of a compassionate image intervention in patients 
with delusions (Ascone et al., 2017). In both cases, the authors conclude that the intervention needs to 
be intensified, since negative self-related beliefs in patients with paranoia are likely to be deeply 
engrained. Thus, while targeting worry via brief interventions seems a promising approach to reduce 
delusions, effective interventions to reduce persistent negative self-concepts are unlikely to be brief, 
and may require booster sessions to ensure enduring change. 
The results of the eight hallucinations studies reviewed were generally positive, with effect sizes 
on primary outcomes ranging from small-to-moderate (0.44; Birchwood et al., 2014) to very large (1.78; 
Hazell et al., In Press). In the studies that included a follow-up group comparison the effects were 
generally maintained, but the follow-up periods were relatively brief (nine months post-therapy being 
the longest (Birchwood et al., 2014)). Effects on secondary outcomes were more varied. All studies 
found effects on at least one measure assessing power beliefs, supporting the view that changing the 
power imbalance and omnipotence appraisals is a common ingredient to all the interventions. However, 
with some notable exceptions, fewer studies impacted on voice-related distress, depression, general 
psychopathology, or functioning. 
Two studies on hallucinations (Craig et al., In Press; Shawyer et al., 2012) and one on delusions 
(O'Connor et al., 2007) included an active control, but only the Avatar trial (Craig et al., In Press) was 
powered for an active control comparison. Even against a supportive counselling group, this brief 
intervention was significantly superior, with group differences on almost all of the auditory 
hallucinations outcome measures at the end of treatment. Furthermore, the effect size on their primary 
outcome (0.8) was larger than the effects achieved by generic CBTp in relation to voices compared to 
TAU (0.44; van der Gaag et al., 2014). However, although the improvements were maintained at the 24-
weeks follow-up, the supportive counselling group showed a small improvement post-therapy, such that 
group effects were no longer significant. Future research will need to test whether additional sessions of 
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Avatar Therapy or a more intensive focus on specific mechanisms may provide longer-term benefits, or 
whether the type of ‘augmented’ supportive counselling offered in the control group, provided by 
experienced psychosis clinicians, may be sufficient to address distressing persecutory voices. 
  
Comparisons across trials 
It is difficult at this stage to draw firm conclusions about the relative superiority of one approach 
over others, since only one of the delusions studies (Freeman et al., 2015a) and two of the hallucinations 
studies (Birchwood et al., 2014; Craig et al., In Press) were sufficiently powered, and several trials failed 
to predefine a primary scale/subscale and time-point. The possibility to pick and choose between 
subscales and time-points can create a bias towards an over-optimistic interpretation of findings. As 
would be expected, generally the pilot studies reported larger effect sizes than the more 
methodologically robust and larger trials. Another source of bias is the fact that with one exception 
(O'Connor et al., 2007), all the interventions were developed by those leading or involved in the trial, 
potentially leading to allegiance effects. These sources of bias need to be kept in mind when comparing 
the studies to each other, and especially when comparing the effect sizes to those found in recent meta-
analyses of generic CBTp that include numerous trials, in which allegiance effects have become less 
relevant over time. 
Nevertheless, there are some tentative observations in relation to the hallucinations trials that 
will be worth following up. Although CTCH almost halved the rate of compliance with command 
hallucinations, which was mediated by a change in power differential between the voice and voice-
hearer (Birchwood et al., 2017), voice-related distress did not differ across groups (Birchwood et al., 
2014). In contrast, Avatar Therapy reduced both the frequency and distress associated with voices. 
Relating Therapy and a guided self-help CBTv intervention also showed large effects on distress and 
impact of voices, respectively, albeit in pilot trials with much smaller samples. It is possible that these 
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discrepancies were partly due to the severity of the command hallucinations in the COMMAND trial, 
which may be inherently more distressing than non-command hallucinations. However, the ‘exposure’ 
to an avatar of patients’ personified voice is likely to be a uniquely powerful tool in reducing fear and 
distress associated with persecutory voices, similarly to exposure-based therapies in Post-Traumatic 
Stress Disorder (PTSD; Grey et al., 2002), although its technological requirements may make it difficult to 
implement in routine services. The emphasis on ‘homeworks’, through instructions to listen to audio-
recordings of sessions in Avatar Therapy, and the use of a workbook in guided self-help CBTv, may have 
also facilitated reductions in the emotional impact of voices. Another possibility is that not enough 
emphasis was given in CTCH to addressing subordinate schema and wider interpersonal relationships, 
since not all patients reached that stage of the therapy, which came late in the protocol (see Meaden et 
al., 2013). Changing the negative ‘relating’ to voices and other people in their social world is the main 
focus of Relating Therapy, and both COMET and the guided self-help CBTv protocol also focused on 
increasing assertiveness in wider relationships. It is possible that these factors represent the crucial 
component for distress and depression to be reduced, although it remains unclear whether such 
improvements are maintained over longer time periods. 
Length of therapy diverged widely across studies, ranging from 4-8 sessions (Avatar Therapy; 
COMET; guided self-help CBTv; focused interventions for paranoia) to 24 or 25 sessions (CBT for 
delusional disorder; CTCH). It would be imprudent to draw any conclusions about the relative benefits of 
brief versus lengthy interventions. Two recent meta-analyses attempted to address this issue by 
selecting trials with fewer than 16 sessions (10 trials; Hazell et al., 2016) or lasting less than four months 
(7 trials; Naeem et al., 2016). Both reported moderate effect sizes for the shorter interventions, with the 
authors suggesting that such interventions could be used in their own right to increase access. However 
both studies confounded brevity with targeted therapies, meaning it was not possible to disentangle 
whether the positive effects were due to brief therapies being equally effective as more traditional, 
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lengthy CBTp, or due to the research strategy of focusing on an isolated outcome/process being more 
effective than the evaluation of a generic therapy in heterogeneous samples. Nevertheless, some of the 
briefer interventions reviewed here (Avatar Therapy; guided self-help CBTv) showed some of the highest 
effect sizes, although further work needs to establish the longevity of their effects. Overall, our review 
suggests that targeted interventions might not necessarily have to be long to be effective, at least on 
specific outcomes addressed by the therapy. 
 There was a wide range of dropout rates from therapy across RCTs, but in the three trials that 
included a therapy control group drop-out was consistently higher in the control therapy. Drop-out rates 
were generally higher in the hallucination compared to the delusion trials, potentially due to the highly 
distressing and often shaming content of voices making such patients more ambivalent about therapy. 
Alternatively, the focus on causal factors, such as worry and self-concept in the delusion trials, may have 
made these interventions less daunting than a direct focus on distressing beliefs, and therefore more 
acceptable to patients 
Comparisons across interventions 
While the interventions for delusions have focused primarily on the causal mechanisms 
approach, the symptom-focused approaches to hallucinations have taken a somewhat different route. 
The tendency has been for each group to have a new label for their therapy, with varying degrees of 
distancing itself from the traditional CBT model. Close inspection of the different interventions revealed 
that they have more in common than they have differences, although the therapeutic procedures 
utilized to bring about change differed across studies. It seems clear that the main aim of all 
interventions for voices was to modify the perceived power imbalance of what is essentially an 
interpersonal relationship between the voice(s) and the voice-hearer, and hypothesized to lead to 
distress and dysfunction. They all also included experiential elements embedded in the therapy to 
facilitate cognitive and emotional change, be that through the use of behavioural experiments (CTCH), 
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mindfulness exercises (TORCH), assertiveness training and role-plays (Relating Therapy), imaginal re-
living (of counter-memories; COMET), use of a workbook (guided self-help CBTv), or a computerized 
visual and auditory representation of the voice (Avatar Therapy). 
However, the different therapies diverge in terms of emphasis on specific therapeutic target(s), 
ranging from a central focus on changing omnipotence appraisals and reducing harmful compliance and 
safety behaviours (CTCH), through improving wider social relationships (Relating Therapy), to reducing 
the noxious impact of the negative content of voices (Avatar Therapy; COMET). There are also subtle 
variations in terms of the particular hallucinations dimension used as primary outcome, reflecting the 
differing therapeutic emphasis of the studies. Of note, the only therapy to make any claims about its 
potential in reducing the actual severity and frequency of hallucinations is Avatar Therapy, which did 
indeed demonstrate a significant decrease in voices frequency at the end of treatment (Craig et al., In 
Press). Birchwood and colleagues (Birchwood and Trower, 2006) have previously argued that 
psychological therapies are not ‘pseudo-neuroleptics’, and are only likely to impact on the psychological 
dimensions associated with voices such as behaviour, appraisals and distress. It remains to be seen 
whether the use of powerful digital technology may enable the actual hallucinatory experience to be 
altered over a sustained period of time. 
 
Limitations of the review   
Our strict inclusion criteria meant that some potentially relevant studies were not included. For 
instance, reasoning biases are another factor associated with delusions, and have been targeted by 
reasoning training (see Ward and Garety, In Press) and meta-cognitive training (Eichner and Berna, 
2016). These approaches share common principles with CBTp, which can also operate at the ‘process’ 
level, but were excluded as they typically consist of a manualized training approach. Another causal 
mechanism is sleep, which was improved successfully in a pilot trial by Freeman’s group (Freeman et al, 
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2015b), with inconclusive effects on delusions and hallucinations. This study did not fulfil our inclusion 
criteria due to its broader focus. There have also been some promising findings on the impact of 
Mindfulness-Based Cognitive Therapy on voice-related distress and mood (Chadwick, 2014; Chadwick et 
al., 2016), which were not included due to the therapy being group-based rather than individual. 
Although we report effect sizes to attempt to establish some comparability between trial outcomes, 
several issues need taking into account. One is that effect sizes are influenced by the heterogeneity of 
the sample, with small standard deviations producing larger effect sizes. Thus, it is not clear whether 
studies with targeted interventions have higher effect sizes than generic CBTp because the interventions 
are more effective, or because the samples are more homogeneous. Another issue is the heterogeneity 
in outcome measures used. For instance, although all but one of the trials focusing on voices used the 
PSYRATS-AH, the way that the scores were calculated diverged across studies, with some using single 
items, others using the total and subscales scores reported in the original scale, and yet others using the 
dimensions derived by Woodward and colleagues (2014). The voice-impact subscale of the HPSVQ (Van 
Lieshout and Goldberg, 2007) is a promising outcome measure that warrants further attention, bearing 
in mind the very large effect size found by the one study that used it instead of the PSYRATS-AH as its 
primary outcome (Hazell et al., In Press). Thus, although the choice of inclusion criteria, measures, 
delivery and outcome time-points generally was well justified in the studies, the heterogeneity of 
research designs makes it difficult to compare the efficacy of approaches even within a highly focused 
review such as this one. 
Future research directions 
There are a number of other potential maintenance or causal factors, for both hallucinations and 
delusions, which could be targeted by future trials. For instance, building on the crucial role of stress-
sensitivity (Myin-Germeys and van Os, 2007), the effect of targeting physiological stress-regulation (e.g. 
heart-rate variability) has been piloted in several brief biofeedback interventions in a range of samples, 
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and found promising for both physiological stress adaptation and paranoia (Breitborde et al., 2015; 
Clamor et al., 2016). A crucial factor in maintaining distressing beliefs is the use of safety behaviours. 
Freeman and colleagues (2016a) used a Virtual Reality experimental study to demonstrate that it was 
the dropping of safety behaviours, rather than exposure to the feared environment alone, which led to 
large reductions in delusional conviction and distress. Such approaches could also be used to test the 
impact of dropping safety and appeasement behaviours on voice power appraisals and compliance 
behaviour. 
Taken together, the interventionist-causal model approach (Kendler and Campbell, 2009) seems a 
promising research strategy in terms of both evaluating the efficacy of specific components or processes 
of psychological interventions for psychotic symptoms, and improving our understanding of mechanisms 
central to their maintenance. However, it can also potentially be a laborious approach, given the multi-
faceted aetiology of both delusions and hallucinations, and several candidate mechanisms remain to be 
evaluated. One of the next steps currently being undertaken is to combine the effective stand-alone 
interventions into a more comprehensive therapy (Freeman et al., 2016b). While this approach returns 
to the original starting point of CBTp i.e., adapting the content of therapy flexibly according to patients’ 
heterogeneous presentations, it has the benefit that each component has been demonstrated to be 
efficacious empirically, unlike generic CBTp. 
There were no studies focusing on delusions other than persecutory beliefs, and hallucinations other 
than voices. It therefore remains to be seen whether the approaches reviewed here would be equally 
effective for other types of delusions, such as grandiose or religious delusions, or other types of 
hallucinations, such as visions or somatic hallucinations, or whether new variants need to be developed. 
A strength of the studies reviewed is that most have moved away from using symptom severity as 
the most relevant outcome to measure, thereby bringing the research in line with the focus taken in 
clinical practice, which is to target distress and dysfunction. To increase comparability beyond symptoms, 
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it would also be helpful for the CBTp research community to agree on including in all trials a common 
outcome relating to the overarching aims of therapy, such as well-being or social and occupational 
functioning. 
Finally, the symptom focused research offers an opportunity to move beyond psychosis 
diagnoses, and target delusions and hallucinations in other disorders. Such a transdiagnostic approach 
has already been espoused by most of the hallucinations trials in this review, which included individuals 
with affective disorders diagnoses with psychotic symptoms (ICD-10 F30-39). Future trials may wish to 
widen their inclusion criteria to individuals with borderline personality disorder or PTSD, among others, 
where hallucinations are prominent (Kelleher and DeVylder, 2017) and tend to go untreated, or have no 
diagnostic inclusion criteria at all, such as in the trials by Hayward and colleagues (2017) and Hazell and 
colleagues (In Press). 
 
Clinical implications 
It is important not to confuse a research strategy that takes a symptom-approach, and targets 
one component of therapy at a time to determine the effective ingredients of therapeutic change, with 
the development of ‘new’ or ‘low-intensity’ treatments. The approaches reviewed here all draw on 
cognitive behavioral models of psychosis and share similar underlying principles. Thus, in our view it is 
more helpful to present this body of work to clinicians as representing different foci of therapeutic work 
that have been demonstrated to be effective, rather than being sold as new and briefer treatments that 
are more effective than CBTp, while keeping in mind that some of the approaches reviewed here need 
further and more rigorous evaluation before disseminating them at all. Furthermore, in clinical practice 
delusions and hallucinations generally do not occur in isolation from each other, and the interventions 
reviewed here are thus probably best used in combination, according to the formulation for different 
presentations and identified barriers to the person’s personal valued goal(s). 
Review of CBT for delusions and hallucinations 
Table 1. Details on reviewed studies with focus on delusions 
Reference Country N Patient population Intervention (n) Therapy format 
Measurement  
time points 
Blinded 
study 
Dropout
a
 
Controlled effect sizes for 
primary outcome measure(s)
b
 
Controlled effect 
sizes  for key 
secondary 
outcome 
measures
 b
 
O’ Connor 
et al. 
(2007) 
Canada 24 Outpatients with a 
diagnosis of delusional 
disorder and no other 
psychotic or other major 
problems on Axis I or II of 
DSM-IV 
 
Intervention group 
(12)  = CBT aimed at 
challenging delusions 
(cognitive challenge 
and reality testing) 
 
Attention placebo 
control group (12; 
APC) to control for 
therapeutic 
encounters and 
nonspecific 
supportive effects 
Individual, 24 
weekly sessions 
 
administered by: 
licensed clinical 
psychologists 
specialized in CBT 
for delusional 
disorder 
- baseline 
- post-treatment 
(24 weeks after 
baseline) 
 
yes lost to post-
treatment:  
CBT: 8% 
APC: 50% 
 
Drop-out 
from therapy: 
CBT: 17-25%
e 
APC: 50% 
MADS dimensions (all single 
items) 
- subjective conviction: ƞp
2
 = 0.16
d
  
- decrease in idiosyncratic 
emotion: ƞp
2
 = 0.26
d 
- acting against the belief: ƞp
2
 = 
0.28
d 
- reaction to belief: trend in favor 
of CBT; ƞp
2
 = 0.18
d
 (trend, p =.05) 
- harm attempted due to belief: 
ƞp
2
 = 0.28
d 
 
no significant effects found for  
the other 10 MADS items 
 
  
BAI: n.s
c
 
BDI: ƞp
2
 = 0.74
d
 
 
other measures 
used: BABS 
(served only as 
check on 
reliability), SSEI 
 
Foster et 
al. (2010) 
 
UK 24 Inpatients and 
outpatients with a 
diagnosis of 
schizophrenia, 
schizoaffective disorder, 
or delusional disorder, a 
significant level of worry 
(PSWQ ≥ 45) and 
persistent persecutory 
delusions (> 6 months) 
Intervention group 
(12) = brief CBT 
aimed at reducing 
worry by targeting 
beliefs about worry 
and worry related 
behavior  
 
TAU
f  
(12) 
Individual; 4 
sessions over one 
month 
 
administered by: 
fist author with 
supervision  
- baseline (before 
randomization) 
- end of treatment 
(1 month after 
randomization) 
- follow up (2 
months after 
randomization) 
no lost to post-
treatment:  
CBT: 25% 
TAU: 8% 
 
lost to follow 
up:  
CBT: 17% 
TAU: 17% 
 
Drop-out 
from therapy: 
8% 
 
additionally calculated controlled 
effect sizes
b
  
PSWQ:  
d = 0.67 (at 1 month) 
d = 0.99 (at 2 months) 
GPTS-distress: 
d = 0.30
  
(at 1 month); n.s. 
d = 0.71 (at 2 months); n.s. 
 
 
PSYRATS-
Delusions total:  
d = 1.49 (at 1 
month)  
d = 1.35 (at 2 
months) 
GPTS-persecution: 
d = 0.22
  
(at 1 
month); n.s. 
d = 0.57 (at 2 
months); n.s. 
other measures 
used: WTAR 
Freeman 
et al. 2014 
UK 30 Outpatients (18-70 years) 
with a diagnosis of 
schizophrenia, 
schizoaffective disorder, 
or delusional disorder, 
negative beliefs about the 
self (assessed in the BCSS) 
and current persecutory 
delusions (PSYRATS 
delusion conviction ≥ 3) 
 
Intervention group 
(15)  
= brief CBT 
aimed at improving 
self-confidence by 
targeting beliefs 
about self and 
enhancing positive 
activity 
 
TAU
f
 (15) 
 
 
Individual; 6 
sessions over 8 
weeks 
 
administered by: 
clinical 
psychologists with 
support from 
graduate 
psychologist 
- baseline 
- post-treatment 
(8weeks after 
baseline) 
-follow-up (12 
weeks after 
baseline) 
yes lost to post-
treatment:  
CBT: 0% 
TAU: 7% 
 
lost to follow 
up:  
CBT: 0% 
TAU: 0% 
 
Drop-out 
from therapy: 
0% 
 
Post-assessment: 
BCSS-negative:  
d = 0.24
 
n.s.  
GPTS: d = 0.59
 
n.s.  
 
no benefits on primary outcomes 
were maintained at 12 week 
follow-up.  
 
 
PSYRATS-
Delusions total: d 
= 0.91
 
n.s. 
BCSS-positive:  
d = 1.00 
SCS: d = 0.88  
RSQ: d = 0.62 
other measures 
used: WEMWBS, 
BAI, BDI-II 
 
no benefits on 
secondary 
outcomes were 
maintained at 12 
22 
 
 week follow-up 
Freeman 
et al. 
(2015) 
UK 150 Inpatients and 
outpatients with a 
diagnosis of 
schizophrenia, 
schizoaffective disorder, 
or delusional disorder, a 
significant level of worry 
(PSWQ ≥ 45) and 
persisting persecutory 
delusions (> 6 months; 
PSYRATS delusion 
conviction ≥ 3). 
 
Intervention group 
(73) = aimed at 
reducing worry by 
targeting beliefs 
about worry and 
worry related 
behavior  
 
TAU
f
 (77) 
 
Individual; 6 
sessions over 8 
weeks 
 
administered by: 
clinical 
psychologists with 
supervision 
- baseline 
- post-treatment 
(8 weeks after 
baseline) 
- follow up (24 
weeks after 
baseline) 
yes lost to post-
treatment:  
CBT: 4% 
TAU: 5% 
 
lost to follow 
up:  
CBT: 7% 
TAU: 5% 
 
Drop-out 
from therapy: 
12% 
 
 
Differences in average outcome 
across post and follow-up 
assessment 
PSWQ: d = 0.47 
PSYRATS-delusions: d = 0.49
  
 
 
Differences in 
average outcome 
across post and 
follow-up 
assessment 
GPTS: d = 0.45 
PSYRATS-distress:  
d = 0.41 
PANSS: d = 0.42 
PTQ: d = 0.32 
other measures 
used:  CHOICE, 
WEMBWS 
Note. BAI = Beck Anxiety Inventory (Beck and Steer, 1993); BABS = Brown Assessment of Beliefs Scale (Eisen et al., 1998); BCSS = Brief Core Schema Scale (Fowler et al., 2006); BDI = Beck Depression Inventory (Beck et al., 
1961); BDI-II = Beck Depression Inventory II (Beck et al., 1996); CHOICE = Choice of Outcome in CBTp (Greenwood et al., 2010); GPTS = Green et al Paranoid Thoughts Scale (Green et al., 2008); MADS = Maudsley Assessment 
of Delusion Schedule (Wessely et al., 1993); PANSS = Positive and Negative Syndrome Scale for Schizophrenia (Kay et al., 1989); PSWQ = Penn State Worry Questionnaire (Startup and Erickson, 2006); PSYRATS-delusion = 
Psychosis Rating Scales-delusion (Haddock et al., 1999); PSYRATS-distress = Psychosis Rating Scales-distress (Haddock et al., 1999); PTQ = Perseverative Thinking Questionnaire (Ehring et al., 2011) ; RSQ = Robson Self-
Concept Questionnaire (Robson, 1989); SCS = Social Comparison Scale (Allan and Gilbert, 1995); SSEI = Social Self-Esteem Inventory (Lawson et al., 1979); WEMWBS = Warwick-Edinburgh Mental Well-being scale (Tennant et 
al., 2007); WTAR = Wechsler Test of Adult Reading (Wechsler, 2001) 
 
a 
as calculated from flow-chart (lost from randomization to post-assessment; lost from randomization to follow up) for therapy and control group, for primary outcome; drop-out rates from therapy are also reported 
separately (includes treatment refusers (post-randomisation) + drop-out from therapy (pre-defined definitions for minimum number of sessions were used if those were reported in paper)
 
b 
The scale/ subscales defined as primary outcomes are underlined. Effect sizes are as reported in original papers; if no effect size was reported, additional controlled effect sizes were calculated as mean group 1 – mean 
group 2 at post-treatment or follow-up/pooled standard deviation of both groups at baseline. 
c  
exact effect size not reported in paper
 
d 
effect sizes reported in paper are partial eta-squared: weak = 0.17, medium = 0.24, strong = 0.51, very strong = 0.70 
e
 conflicting rates are reported in the paper 
f
 TAU = treatment as usual/standard care 
 
  
Review of CBT for delusions and hallucinations 
Table 1. Details on reviewed studies focusing on hallucinations (presented chronologically) 
Reference Country N Patient population Intervention (n) Therapy format 
Measurement  
time points 
Blinded 
study 
Dropout
a
 
Controlled effect sizes
 
for primary outcome 
measure(s)
b
 
Controlled effect sizes
 
for key secondary 
outcome measures
b
 
Trower et 
al. (2004) 
UK 38 Patients with 
schizophrenia or related 
condition having 
experienced command 
hallucinations for at 
least 6 months with 
recent history of harm 
to self or others, or 
major social 
transgressions as a 
result of the commands 
 
Intervention group 
(18) = cognitive 
therapy for 
command 
hallucinations 
(CTCH; as 
Birchwood et al 
2014) 
 
TAU
c
 (20) 
as Birchwood et al 
2014 
- baseline 
- post-treatment 
(6 months after 
baseline) 
- follow up (12 
months after 
baseline) 
yes Post-treatment 
CTCH: 17% 
TAU: 15% 
 
Follow-up 
CTCH: 22% 
TAU: 25% 
 
Drop-out from 
therapy: 27% 
 
VCS:  
d = 1.1 (6 months) 
 
additionally calculated 
effect sizes
b
  
 
d = 3.40 (12 months)
d 
 
additionally calculated 
effect sizes
b
  
 
VPD total:  
d = 1.42 (6 months) 
d = 1.70 (12 months) 
BAVQ-malevolence:  
d = 0.19
 
(6 months; n.s.) 
d = -0.13
 
(12 months; 
n.s.) 
BAVQ-omniscience:  
d = 0.37 (6 months) 
d = 0.30 (12 months)
 
PSYRATS-control (1 
item): 
d = 1.33 (6 months) 
d = 1.48 (12 months) 
PSYRATS-distress (1 
item): 
d = 1.11 (6 months) 
d = 0.48
 
(12 months; 
n.s.) 
 
other measures used:  
PSYRATS-AH (loudness, 
negative content; 
frequency, all 1 item), 
PANSS, CDS 
 
Shawyer 
et al. 
(2012) 
Austra-
lia 
43 Patients (18-65 years) 
with schizophrenia or 
related condition having 
experienced command 
hallucinations within the 
previous 6 months 
causing distress or 
dysfunction (NB 
presence of current 
compliance behavior 
was not an inclusion 
criteria) 
Intervention group 
(21) = treatment of 
resistant command 
hallucinations 
(TORCH). CBT aimed 
at changing voice 
power beliefs, 
augmented with 
Acceptance & 
Commitment 
Therapy (ACT) 
strategies 
(noticing/accepting 
voices; 
accomplishing 
valued goals; 
mindfulness 
exercises) 
 
Placebo control 
group (22) = 
Individual; 15 
weekly sessions + 
2 follow-up 
sessions; 
50min/session 
 
administered by: 
therapists trained  
according to 
TORCH or 
Befriending 
manuals under 
supervision  
- baseline 
- post-treatment  
- follow up (6 
months after end 
of treatment) 
yes Post-treatment 
TORCH: 5-10% 
(dependent on 
outcome) 
Befriending:14
% 
 
Follow-up 
TORCH: 14-
24% 
(dependent on 
outcome) 
Befriending: 
18-23% 
(dependent on 
outcome) 
 
Drop-out from 
therapy:  
TORCH=5% 
Befriending=9
Adapted interview on 
compliance and coping 
with harmful command 
hallucinations  
(compliance; coping; 
resistance  (single 
items); Shawyer et al., 
2008) 
 
TORCH vs. Befriending 
Compliance:  
could not be analyzed 
(only 18/43 complied at 
baseline)  
Resistance:  
d = -0.07 (endpoint; n.s) 
d = -0.05  (6 months; n.s) 
Coping:  
d = -0.31
 
(endpoint; n.s) 
d = 0.04
 
(6 months; n.s) 
TORCH vs. Waitlist 
TORCH vs. Befriending 
PANSS-total:  
d = 0.60 (endpoint; n.s.) 
d = 0.09 (6 months; n.s.) 
PSYRATS-AH distress (2 
items: intensity + 
amount):     
d = -0.37
 
(endpoint; n.s)
 
d = -0.06 (6 months; n.s) 
PSYRATS-AH disruption 
(1 item):     
d = -0.52
 
(endpoint; n.s) 
d = -0.06
 
(6 months; n.s)
 
 
TORCH vs. Waitlist 
PANSS total: d = 1.01 
PSYRATS-distress:     
d = -0.13 (n.s.) PSYRATS-
disruption:    d = 0.51
 
(n.s.) 
other measures used: 
24 
 
befriending 
 
waitlist control 
group (17; 
subsample: before 
randomization) 
% 
 
Resistance: 
d = 0.64
 
(n.s.) 
Coping:  
d = 1.07 
 
modified-GAF, Voice-
related distress (single 
item from SHER), QoL-
ESQ;  
 
Process measures: 
VAAS, BAVQ-R, RSQ, 
Voice-related 
preoccupation and 
insight (single items 
from SHER), BIS 
 
van der 
Gaag et al. 
(2012) 
 
 
Nether-
lands 
77 Patients with 
schizophrenia-spectrum 
disorder with persistent 
auditory verbal 
hallucinations of daily 
occurrence (PSYRATS-AH 
item 1 ≥2), with at least 
moderately intense 
suffering (PSYRATS-AH 
item 9 ≥2) and at least 
moderate disturbance of 
daily living (PSYRATS-AH 
item 10 ≥2) 
Intervention group 
(39) = competitive 
memory training 
(COMET). Therapy 
aimed at enhancing 
self-esteem and 
changing 
relationship 
between voice and 
voice-hearer from 
submissive to 
distant through 
experientially 
changing negative 
content of voice 
and its association 
with self-esteem 
 
TAU
c
 (38) 
Individual; 7 
sessions 
 
administered by: 
no information 
- baseline 
- post-treatment 
(2 months after 
baseline) 
yes Post-treatment 
COMET: 28%
e 
TAU: 0% 
 
Drop-out from 
therapy: 28% 
 
 
BDI-II:  
d = 0.64 
 
PSYRATS-AH total:  
d = 0.30
 
(n.s.) 
PSYRATS-AH (3-factor 
version (Haddock et al, 
99)): cognitive 
interpretation (3 items): 
d = 0.63 
 
other measures used:  
PSYRATS-AH (physical 
characteristics 4 items: 
frequency, duration, 
location, loudness); 
negative emotional 
content (4 items: 
negative content, 
distress) 
 
Leff et al 
(2013) 
UK 26 Patients (14-75 years) 
hearing persecutory 
voices for at least 6 
months (irrespective of 
diagnosis) and not 
responded to medication 
Intervention group 
(14) = computer-
assisted therapy for 
medication-
resistant auditory 
hallucinations 
(avatar therapy; as 
Craig et al, 2017).  
 
TAU
c
/ 
delayed therapy 
(12) 
 
Individual; 6 
weekly sessions + 
1 follow-up 
session; 
30min/session 
 
administered by: 
first author 
- baseline 
- post-treatment 
for immediate 
therapy 
group/pre-
treatment for 
delayed therapy 
group (7 weeks 
after baseline) 
- follow up (3 
months after 
treatment) 
 
yes Post-treatment 
Immediate 
therapy: 43% 
Delayed 
therapy group 
(during TAU): 
0% 
Delayed 
therapy group 
(post-
treatment): 
33% 
 
Follow-up: 
no information 
 
Drop-out from 
therapy: 35% 
 
 
additionally calculated 
controlled effect sizes
bfe
 
 
PSYRATS-AH total: d = 
1.62 
BAVQ-R: d = 0.26 
CDS: d = 0.04
 
(n.s.)
 
 
no follow-up between-
group comparison 
None 
Birchwood 
et al. 
(2014) 
UK 197 Patients (16 or older) 
with schizophrenia, 
schizoaffective or mood 
Intervention group 
(98) = cognitive 
therapy for 
Individual; about 
25 sessions over a 
maximum of 9 
- baseline 
- post-treatment 
(9 months after 
yes Post-treatment 
CTCH: 13% 
TAU: 10% 
VCS:  
OR
g
 = 0.45 (18 months) 
OR
g
= 0.57 (common to 9 
additionally calculated 
controlled effect sizes
b
  
VPD total: d= 0.37 
25 
 
disorders and a history 
of harmful command 
hallucinations for at 
least 6 months, with 
recent (<9 months) 
history of harm 
to self or others, or 
major social 
transgressions as a 
result of the commands,  
or appeasement of 
voices 
command 
hallucinations 
(CTCH). CBT aimed 
at reducing harmful 
compliance through 
changing voice 
power and control 
appraisals and 
reducing power 
differential 
between voice and 
voice-hearer (see 
Meaden et al, 2013)   
 
TAU
c 
(99) 
months; 
1h/session 
 
administered by: 
nine cognitive 
therapists under 
supervision by a 
lead clinician with 
expertise in CBTp 
baseline) 
- follow up (18 
months after 
baseline; primary 
time-point for 
VCS) 
 
Follow-up  
CTCH: 19% 
TAU: 14% 
 
Drop-out from 
therapy: 19% 
 
+ 18 months)  
 
additionally calculated 
controlled effect sizes
b
  
VCS:  
d = 0.44 (18 months) 
d = 0.31 (common to 9 + 
18 months) 
 
(common to 9 + 18 
months)  
VPD power: d = 0.41 
(common to 9 + 18 
months) 
No other measure 
significant 
 
other measures used:  
BAVQ-R, PSYRATS-AH 
total, PSYRATS-AH 
distress (2 items: 
intensity + amount), 
PKQOS, CDS, BHS, BSSI 
 
Hayward 
et al 
(2017) 
UK 29 Patients (18 years or 
older) with distressing 
auditory hallucinations 
for at least one year 
(irrespective of 
diagnosis); scoring 3 or 4 
on either the intensity of 
distress item or the 
amount of distress item 
on the PSYRATS-AH at 
time of consent; 
currently receiving 
specialist mental health 
care 
Intervention group 
(14) = relating 
therapy. Therapy 
aimed at  reducing 
voice distress and 
power differential 
between voice and 
voice-hearer 
through changing 
interpersonal 
‘relating’ with voice 
and  assertiveness 
training (see 
Hayward et al, 
2014) 
 
TAU
c
 (15) 
Individual, up to 
16 weekly 
sessions; 
1h/session 
 
administered by: 
four clinical 
psychologists and 
one nurse 
consultant (two 
therapists familiar 
with the therapy; 
three received 
training) 
- baseline 
- post-treatment 
(16 weeks after 
baseline) 
- follow up (36 
weeks after 
baseline) 
yes Post-treatment 
Relating 
therapy: 0% 
TAU: 13% 
 
Follow-up  
Relating 
therapy: 14% 
TAU: 7% 
 
Drop-out from 
therapy: 7% 
 
PSYRATS-AH distress
h
 (5-
item component: 
negative content 
(amount + degree), 
distress (amount + 
intensity), control, from 
4-factor version at t1 
(Woodward et al, 2014):  
d = 1.3 (16 weeks) 
d = 1.4 (36 weeks) 
PSYRATS-AH total
h
 
d = 1.4 (16 weeks) 
d = 1.2  (36 weeks) 
CHOICE-satisfaction
h 
d = 0.7 (16 weeks) 
d = 0.5 (36 weeks) 
CHOICE-severity
h 
d = 0.9 (16 weeks) 
d = 0.7 (36 weeks) 
HADS-anxiety
h
 
d = 0.4 (16 weeks) 
d = 0.2 (36 weeks) 
HADS-depression
h
 
d = 0.7  (16 weeks) 
d = 0.9 (36 weeks) 
 
other measures used:  
PSYRATS-AH (other 3 
components from 4-
factor version:  
frequency (3 items: 
frequency; duration; 
disruption); attributions 
(2 items: location; 
origin); loudness (1 
item) 
 
process  measures used:  
VAY, PROQ3 total 
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Hazell et al 
(In Press) 
UK 28 Patients (18 years or 
older) with distressing 
auditory hallucinations 
for at least one year 
(irrespective of 
diagnosis); scoring at 
least 3 on either item 5, 
6 or 7 (voice 
interference; distress; 
impact on self) of 
HPSVQ, at time of 
consent; currently 
receiving specialist 
mental health care 
Intervention group 
(14) = guided self-
help CBT for voices 
(CBTv). Therapy was 
based on 
‘Overcoming 
Distressing Voices’ 
self-help book 
(Hayward et al, 
2012), with 
accompanying 
workbook. Therapy 
aimed to reduce 
voice impact 
through ‘modules’ 
targeted at coping  
with voices, 
reducing negative 
beliefs about self 
and voices,  and 
increasing 
assertiveness in 
relationships.  
 
Wait list TAU
c
 (14) 
Individual, up to 8 
sessions over 12 
weeks; 1h/session 
 
administered by: 
clinical 
psychologists with 
extensive CBTp 
experience  
- baseline 
- post-treatment 
(12 weeks after 
baseline) 
yes Post-treatment 
Guided self-
help CBTv: 7% 
TAU: 0% 
 
Drop-out from 
therapy: 14% 
 
Voice-impact 
subscale of HPSVQ (4 
items, from factor 
analysis by Kim et al, 
2010) 
d = 1.78 
HPSVQ total 
d = 1.20 
CHOICE-severity
 
d = 1.40 
CHOICE- Goals (2 items)
 
d = 1.54 
HADS-anxiety 
d = 0.94 
HADS-depression 
d = 0.27 (n.s.)   
 
other measures used:  
SWEMWBS, RSES
i 
 
process  measures used:  
BCSS (self-scale), PROQ3 
total, VAY, BAVQ-R, 
HPSVQ phenomenology 
subscale
i
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Craig et al 
(In Press) 
UK 150 Patients (18 years or 
older) with 
schizophrenia, 
schizoaffective or mood 
disorders (ICD-10  F20-
39) and distressing 
auditory hallucinations 
for at least 12 months 
despite antipsychotic 
medication 
Intervention group 
(75) = computer-
assisted therapy for 
medication-
resistant auditory 
hallucinations 
(avatar therapy). 
Therapy aimed at 
reducing voice 
power, increasing 
control and self-
esteem, and  
reducing power 
differential 
between voice and 
voice-hearer 
through exposure 
to/assertive 
dialogue with voice 
(through avatar) 
(see Leff et al, 2014; 
Craig et al, 2016) 
 
Placebo control 
group (75) = 
supportive 
counselling 
 
Individual; 1 
assessment 
session/setting up 
of avatar + 6 
weekly sessions; 
50min/session 
 
administered by: 
experienced 
clinicians skilled in 
psychological 
therapies; training 
provided by 1
st
 
author of pilot 
study (Leff) 
- baseline 
- post-treatment 
(12 weeks after 
baseline) 
- follow up (24 
weeks after 
baseline) 
yes Post-treatment 
Avatar: 16% 
Counselling: 
19% 
 
Follow-up  
Avatar: 24% 
Counselling: 
23% 
 
Drop-out from 
therapy:  
Avatar: 29% 
Counselling: 
33% 
 
 
PSYRATS-Total at t1: 
d = 0.8 (12 weeks) 
d = 0.3
j
 (24 weeks; n.s.) 
PSYRATS-subscales (4-
factor version; 
Woodward et al, 2014); 
all at 12 weeks (no 
significant effects at 24 
weeks) 
PSYRATS-Frequency: 
d = 0.6 
PSYRATS-Distress: 
d = 0.8 
BAVQ-R omnipotence: 
 
d = 0.5 
BAVQ-R malevolence: 
 
d = 0.3 n.s.) 
VAAS Acceptance:
 
d = 0.5 
VAAS Action: 
d = 0.6 
VPDS total: 
d = 0.4 (n.s.) 
 
other measures used:  
BAVQ-R total, VPDS 
subscales, SAPS, SANS, 
PSYRATS-Delusions, 
DASS-21, CDS, RSES, 
MANSA, MAP
 
 
 
 
Legend: BAVQ-R = Beliefs About Voices Questionnaire-Revised (Chadwick et al., 2000); BDI-II = Beck Depression Inventory-II (Beck et al., 1996); BHS = Beck Hopelessness Scale; (Beck, 1988); BSSI = Beck Scale for Suicidal Ideation 
(Beck et al., 1979) BCSS = Brief Core Schema Scale (Fowler et al., 2006); CDS = Calgary Depression Scale for Schizophrenia (Addington et al., 1993); CHOICE = Choice of Outcome in CBTp (Greenwood et al., 2010); DASS-21 = 
Depression Anxiety and Stress Scale (Lovibond and Lovibond, 1995); GAF = Modified- Global Assessment of Functioning Scale, DSM-IV version (Hall, 1995a; Hall, 1995b); HADS = Hospital Anxiety and Depression Scale;(Zigmond 
and Snaith, 1983) HPSVQ = Hamilton Program for Schizophrenic Voices Questionnaire (Van Lieshout and Goldberg, 2007); MANSA = Manchester Short Assessment of Quality of Life (Priebe et al., 1999) MAP = Maudsley Addiction 
Profile (Marsden et al., 1998); PKQOS = Personal Knowledge Questionnaire and Omniscience Scale (Birchwood et al., 2004); PROQ3 = Person Relating to others Questionnaire (Birtchnell et al., 2013); PSYRATS-AH = Psychosis 
Rating Scales-Auditory Hallucination (Haddock et al., 1999); PSYRATS-delusion = Psychosis Rating Scales-delusion (Haddock et al., 1999); PANSS = Positive and Negative Syndrome Scale for Schizophrenia (Kay et al., 1989); QoL-
ESQ = Quality of Life Enjoyment and Satisfaction Questionnaire (Endicott et al., 1993) ; RSES = Rosenberg Self-Esteem Scale (Rosenberg, 1965) ; RSQ = Recovery Style Questionnaire (Drayton et al., 1998); SAPS = Scale for the 
Assessment of Positive Symptoms (Andreasen, 1984b); SANS = Scale for the Assessment of Negative Symptoms (Andreasen, 1984a); SHER = Single Hallucination Episode Record (Farhall, 2005); SWEMWBS = Short Warwick-
Edinburgh Mental Well-being Scale (Tennant et al., 2007); VAAS = Voice Acceptance and Action Scale (Shawyer et al., 2007); VAY = Voice and You (Hayward et al., 2008); VCS = Voice Compliance Scale (Beck-Sander et al., 1997); 
VPD = Voice Power Differential Scale (Birchwood et al., 2004). 
 
a 
as calculated from flow-chart (lost from randomization to post-assessment; lost from randomization to follow up) for therapy and control group, for primary outcome; drop-out rates from therapy are also reported separately 
(includes treatment refusers (post-randomisation) + drop-out from therapy (pre-defined definitions for minimum number of sessions were used if those were reported in paper) 
 
b
 The scales/ subscales defined as primary outcome are underlined. Effect sizes are as reported in original papers; if no effect size was reported, additional controlled effect sizes were calculated as mean group 1 – mean group 2 
at post-treatment or follow-up/pooled standard deviation of both groups at baseline. When ORs rather than means were reported (Birchwood et al, 2014), they were converted to Cohen’s d using calculator provided in 
http://www.psychometrica.de/effect_size.html#riskratio.   
c
 TAU = treatment as usual/standard care 
d 
The reason for the large discrepancy between the effect size reported in the original paper at 6 months, and the one calculated for the purposes of this review at 12 months, relates to the post-therapy sd having been used in 
the calculation for the former, and the baseline sd for the latter. Effect size for 6 months using baseline sd: d=2.6; effect size for 12 months using follow-up sd: d=1.2.   
e
Flow chart is unclear: it is reported that 11 participants out of 39 ‘withdrew consent’, although all received allocated treatment and 0 were lost to follow-up. Sample sizes at follow-up assessments are not provided in tables, 
although it is reported that 10/28 attained recovery from depression, implying these 11 participants withdrew consent from study as well as therapy, although intention-to-treat analyses were carried out. 
f
An effect size of 0.8 is reported in the article, but it is not clear what measure it refers to and whether it is a pre-post or a controlled effect size
  
g 
OR = Odds Ratio. An OR of .45 means CTCH nearly halved the rate of compliance (46% in CTCH vs. 28% in TAU) 
h 
no information provided on significance of effects 
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i
 RSES is listed as ‘other measure used’ in text, but as ‘mechanism measure’ in results table, and vice-versa for HPSVQ phenomenology subscale 
j
Effect size obtained from study authors 
Review of CBT for delusions and hallucinations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Exclusion of 33 records 
 no RCT (11) 
 theoretical paper/reviews (6) 
 sample not suitable (2) 
 study focus irrelevant (3) 
 no individualized CBT-treatment 
(7) 
 case study (4) 
 
Exclusion of 582 records 
 no RCT 
 pharmacological treatments 
 theoretical paper/review 
 study focus irrelevant 
 sample unsuitable 
 no CBT-treatment 
 
Exclusion of  44 records 
 no RCT (17) 
 theoretical paper/reviews (19) 
 no individualized CBT-treatment (5) 
 Case study (3) 
 
 
 
Delusions 
Identified via Ovid (MEDLINE & PsycINFO)  
Articles after deduplication 
507 records 
Peer-reviewed articles in English 
336 records 
Articles included after abstract-screening 
k = 18 
Exclusion of 285 records 
 no RCT 
 pharmacological treatments 
 theoretical paper/review 
 study focus irrelevant 
 sample unsuitable 
 no CBT-treatment 
 
 
Exclusion of (k = 14) 
 no individualized CBT-treatment 
(4) 
 delusions not primary 
outcome/inclusion criteria (10) 
 
Hallucinations 
Identified via Ovid (MEDLINE & PsycINFO) 
Articles after deduplication 
1293 records 
Peer-reviewed articles in English 
645 records 
Articles included after title-screening 
63 records 
Articles included after abstract-screening 
k = 19
a
 
Articles included after full text-screening 
k = 8 
Exclusion of (k = 11 ) 
 no individualized CBT-treatment 
(4) 
 hallucinations not primary  
outcome/inclusion criteria (3) 
 additional publication on same 
trial (4) 
Articles included after title-screening 
51 records 
Articles included after full text-screening 
k = 4 
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Figure 1. Description of the selection process of studies to be included in the review 
 
a
Two of these studies reported on trial protocols at the time of the literature search but 
were published during the revision process.  
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